IPN Ipsen SA

IPSEN : Déclaration des transactions sur actions propres réalisées du 31/08/2020 au 04/09/2020

PARIS--(BUSINESS WIRE)--

Regulatory News:

Présentation agrégée par jour et par marché

Nom de

l'émetteur

Code identifiant de

l'émetteur (code LEI)

Jour de la

transaction

Code identifiant de

l'instrument financier

Volume total journalier (en

nombre de titres)

Prix pondéré moyen

journalier

d'acquisition

Code

identifiant

marché

IPSEN

549300M6SGDPB4Z94P11

31/08/2020

FR0010259150

2,600

87,3996

XPAR

IPSEN

549300M6SGDPB4Z94P11

31/08/2020

FR0010259150

1,250

87,5082

CHIX

IPSEN

549300M6SGDPB4Z94P11

31/08/2020

FR0010259150

650

87,1843

TRQX

IPSEN

549300M6SGDPB4Z94P11

31/08/2020

FR0010259150

500

87,2705

BATE

IPSEN

549300M6SGDPB4Z94P11

01/09/2020

FR0010259150

4,608

88,8395

XPAR

IPSEN

549300M6SGDPB4Z94P11

01/09/2020

FR0010259150

1,348

88,0851

CHIX

IPSEN

549300M6SGDPB4Z94P11

01/09/2020

FR0010259150

532

88,1094

TRQX

IPSEN

549300M6SGDPB4Z94P11

01/09/2020

FR0010259150

547

88,0685

BATE

IPSEN

549300M6SGDPB4Z94P11

02/09/2020

FR0010259150

0

0

XPAR

IPSEN

549300M6SGDPB4Z94P11

03/09/2020

FR0010259150

1,948

89,0382

XPAR

IPSEN

549300M6SGDPB4Z94P11

03/09/2020

FR0010259150

938

88,9458

CHIX

IPSEN

549300M6SGDPB4Z94P11

03/09/2020

FR0010259150

397

89,1281

TRQX

IPSEN

549300M6SGDPB4Z94P11

03/09/2020

FR0010259150

374

89,1144

BATE

IPSEN

549300M6SGDPB4Z94P11

04/09/2020

FR0010259150

4,363

86,6987

XPAR

IPSEN

549300M6SGDPB4Z94P11

04/09/2020

FR0010259150

2,000

86,7961

CHIX

IPSEN

549300M6SGDPB4Z94P11

04/09/2020

FR0010259150

794

86,7411

TRQX

IPSEN

549300M6SGDPB4Z94P11

04/09/2020

FR0010259150

798

86,7968

BATE

 

 

 

Total

23,647

87,7774

L'information détaillée transaction par transaction des opérations réalisées ainsi que les objectifs de rachat sont disponibles sur le site internet de la société à l'adresse suivante:

FR
08/09/2020

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen update on Phase II FALKON trial in patients with ultra-rare bone...

Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP) PARIS, FRANCE, 19 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and children living with fibrodysplasia ossificans progressiva (FOP) vs. placebo, as a result the study will be closed. The investigational medicinal product (fidrisertib) was generally well tolerated, with no safety concerns in the trial. “These results are ...

15h / 16m 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen fait le point sur l'essai de Phase II FALKON chez les patients a...

Ipsen fait le point sur l'essai de Phase II FALKON chez les patients atteints d’une maladie osseuse ultra-rare, la fibrodysplasie ossifiante progressive (FOP) PARIS, FRANCE – 19 décembre 2025 – Ipsen (Euronext : IPN ; ADR : IPSEY) annonce aujourd'hui que l'essai pivotal de Phase II FALKON n'a pas atteint son critère principal, à savoir la réduction du volume de formation anormale de nouvelle matière osseuse (ossification hétérotopique ou OH) chez l’adulte et l’enfant atteints de fibrodysplasie ossifiante progressive (FOP), par rapport au placebo, en conséquence, l'étude sera clôturée. Le mé...

15h / 16m 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen finalise l'acquisition d'ImCheck Therapeutics, élargissant ainsi...

Ipsen finalise l'acquisition d'ImCheck Therapeutics, élargissant ainsi son portefeuille de produits oncologiques PARIS, FRANCE, 15 DECEMBRE 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd’hui avoir finalisé l'acquisition d'ImCheck Therapeutics, une société privée française de biotechnologie pionnière dans le domaine des thérapies d’immuno-oncologie de nouvelle génération. A propos d’Ipsen Nous sommes un groupe biopharmaceutique mondial focalisé sur la mise au point de médicaments innovants pour les patients dans trois domaines thérapeutiques : l’Oncologie, les Maladies Rare...

December 15, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncolog...

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 year...

December 15, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 49- 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 49- 2025 Aggregated presentation by day and by marketStatement of transactions in own shares from December 1st to December 05th 2025       Name of the issueIdentity code of the issuer (Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P1101/12/2025FR0010259150200124,05000AQEUIPSEN549300M6SGDPB4Z94P1101/12/2025FR0010259150831123,81540CEUXIPSEN549300M6SGDPB4Z94P1101/12/2025FR0...

December 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch